Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital therapy

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

Servier licenses device that could ‘reshape’ diabetes care

Tiny pump implant to deliver GLP-1 agonist

- PMLiVE

NICE wants more evidence on skin damage technologies

But ‘spray-on-skin’ and clothes to prevent ulcers can still be used on NHS

- PMLiVE

NICE backs GSK drug for leukaemia

Arzerra on course for NHS use in blood cancer

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Bayer’s Xarelto wins another NICE recommendation

Deemed cost-effective use of NHS resources to prevent blood clots following a heart attack

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

- PMLiVE

Pressure put on Roche to cut Kadcyla’s UK price

30,000 people sign petition to help make the breast cancer drug available on the NHS

National Institute for Health and Care Excellence NICE logo

NICE working to tackle antimicrobial resistance

Two guidelines in development to improve NHS use of antibiotic drugs

National Institute for Health and Care Excellence NICE logo

NICE publishes its first medicines optimisation guidance

Draft guidelines encourage patient-centred care and improved NHS communications

National Institute for Health and Care Excellence NICE logo

NICE denies two drugs in new MS guidance

Sativex and Fampyra too costly for NHS in England

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links